Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.
In early July, the German Institute for Quality and Efficiency in Health Care conducted two early benefit assessments to investigate whether certain drug combinations with pembrolizumab have advantages in comparison with the respective appropriate comparator therapy for patients with metastatic squamous or non-squamous non-small cell lung cancer.
A big way chemotherapy works is by prompting cancer cells to commit suicide, and scientists have found a pathway the most common lung cancer walks to avoid death.
What if a drug that sits in nearly everyone's medicine cabinet could help extend the lives of some cancer patients? In companion presentations at the American Society for Therapeutic Radiation Oncology Annual Meeting in Chicago, doctors from Roswell Park Comprehensive Cancer Center report new evidence that low-dose aspirin and other anti-inflammatories may improve survival in patients undergoing treatment for some head/neck and lung cancers.
The relationship between gene alterations and response to anti-PD-L1 with and without anti-CTLA-4 are not well characterized.
Patients with non-small cell lung cancer now have more improved treatment options compared to standard of care with the addition of several new agents called immune-checkpoint inhibitors.
Ground-breaking immune therapy promises to deliver vital evidence in the fight against cancer as researchers from the Centre for Cancer Biology open a new clinical trial using genetically engineered immune cells to treat solid cancers.
Since its approval in April 2019, dacomitinib has been available for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor activating mutations.
OTraces, Inc., a molecular diagnostics company specializing in early cancer detection, has announced completion of a preliminary study for detection of pancreatic cancer.
While researchers have a basic understanding of how primary cancer cells grow, less is known about metastasis, the deadly process by which cancers spread.
Treating metastatic non-small cell lung cancer patients with the immunotherapy drug pembrolizumab after they've completed locally ablative therapy – meaning all known sites of their cancer were either treated with surgery, radiation, or other definitive treatments – almost tripled the median progression-free survival compared to the historical average.
When it comes to using radiation against lung cancer, preliminary clinical studies were pretty clear: More is better.
Three beagles successfully showed they are capable of identifying lung cancer by scent, a first step in identifying specific biomarkers for the disease.
As advances in the treatment of non-small cell lung cancer (NSCLC) extend patients' lives, more of these patients are facing a different threat: adverse cardiovascular events, such as heart attacks and heart failure.
Roche Diagnostics today announced the launch of the VENTANA ROS1 Antibody, the first and only in vitro diagnostic ROS1 immunohistochemistry assay. The test detects the presence of ROS1 protein in tissue, and may be useful in identifying ROS1-positive lung cancer cases.
Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response rate of 33 percent of treated patients with early-stage, resectable non-small cell lung cancers, meaning these patients had less than or equal to 10 percent viable tumor remaining at surgery.
In a study led by UCLA investigators, treatment with the immunotherapy drug pembrolizumab helped more than 15% of people with advanced non-small cell lung cancer live for at least five years - and 25% of patients whose tumor cells had a specific protein lived at least that long.
The National Comprehensive Cancer Network Oncology Research Program and AstraZeneca, a global, science-led biopharmaceutical company, are collaborating to seek proposals for improving care processes for patients with unresectable stage III and stage IV non-small cell lung cancer.
For patients with operable non-small cell lung cancer, pre-surgical "neoadjuvant" treatment with an immune checkpoint inhibitor was well tolerated and, in many cases, caused significant tumor cell death in a large, multicenter clinical trial involving investigators at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and nine other research centers
Scientists at VCU Massey Cancer Center may have uncovered a primary method through which cancer cells exist undetected in an organism and received more than $1 million to investigate the potential for novel therapeutics that target and destroy cells in a specific state of tumor dormancy.
Patients who do not smoke are at an increased risk of lung cancer due to air pollution, warns PHE. These patients are often overlooked and diagnosed late, with poor outcomes.